Tau Aggregation Assay Kit

Tau exists in different states in both Alzheimer’s (AD) and Parkinson’s (PD) diseases. Tau aggregation is also a readout for multiple neurodegenerative diseases and CNS disorders.

As all Tau modifications are relevant in biological terms, Cisbio developed a complete range of kits to study the Tau family.

The HTRF Tau aggregation assay detects human Tau aggregates rapidly in brain tissues and cell cultures. This kit is part of our Tau range, including phosphorylated Tau detection and total Tau measurement.

Monitor Tau Aggregation like never before

Monitor Tau Aggregation like never before.

Assay principle

All of Cisbio’s Tau immunoassays were developed in an HTRF sandwich format, with specific antibodies bound to either donor (cryptate) or acceptor (d2) fluorophores. This enables energy transfer when they bind to the same target protein.

Both antibodies in this assay are directed against Tau protein, and the specific signal generated is proportional to the quantity of Tau aggregates.

Only a single reagent needs to be added for this protocol (pre-mixed detection reagents), with incubation from 2 hours to overnight depending on the sample used.

Product specifications

Assay specificity & linearity

A FRET signal is generated in the presence of aggregated tau, leading to a distinctive signal compared to non-aggregated tau. The assay shows a good linear correlation between signal intensity and the purified recombinant tau aggregate concentrations obtained by serial dilutions in assay diluent, with a linear range of 1.9 to 500 ng/mL.

Kinetic of aggregation

Recombinant full length human tau protein was chemically aggregated. The reaction was stopped at different times (1, 2, 4, 6 and 24 h). The samples were previously diluted (1/500) to follow the kinetic of aggregation. This assay could also be used to monitor a kinetic of dissociation after a compound addition. Test performed in 384 well-low volume plate, read on Pherastar FS laser.

Tau aggregation on transgenic mouse brain extracts

Triple-transgenic mice (Tau / PSEN2 / APP) were used as Alzheimer models. These mice develop an Alzheimer-like pathology that starts at 10 months old and progresses over time.

The aim of this experiment was to detect differences in the quantity of Tau aggregates between 10 and 14 month-old mice, in the earlier stages of the disease.

The graph shows that assay sensitivity enables clear discrimination between the  early stages of the fibrillation process. These results correlate with those obtained for Tau phosphorylation.

Part#, inserts & MSDS

Ordering Info

DescriptionCat. noProduct insertMSDS
Tau aggregation kit - 500 tests6FTAUPEG
Tau aggregation kit - 10,000 tests6FTAUPEH